期刊
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
卷 7, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/1710-1492-7-9
关键词
-
资金
- Novartis
- Glaxo Smith-Kline
- Pfizer
- Boehringer
- Nycomed
Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy. Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroidresistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile. Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of nonatopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据